Search Results

You are looking at 121 - 130 of 2,670 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

certificate of participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/84150 ; and 3) view

Full access

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/82684

Full access

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman

Cancer Program from 1998 to 2007 were retrospectively reviewed, with 223 patients being on active surveillance. Vascular invasion was present in 27% of patients, status was unknown in 7%, and embryonal predominance was present in 49%; overall

Full access

Investigational Therapies for Metastatic Thyroid Carcinoma

R. Michael Tuttle and R. Leboeuf

. References 1. Mazzaferri EL Kloos RT . Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer . J Clin Endocrinol Metab 2001 ; 86 : 1447 – 1463 . 2. Hundahl SA Fleming ID Fremgen AM Menck

Full access

Incorporating New Systemic Therapies in Kidney Cancer Treatment

Eric Jonasch

, Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Guidelines Panel, reviewed the state of the art and new systemic therapies incorporated into the 2017 NCCN Clinical Practice Guidelines

Full access

BPI19-018: Cancer Screening Rates and Adherence of Uninsured Cancer Patients in Free Clinics

Katherine Robinson, Amber Todd, Abu-Sayeef Mirza, Madeline Macdonald, Noura Ayoubi, Rahul Mhaskar, Richard Roetzheim, Laurie Woodard, and Smitha Pabbathi

describe the population and statistically significant relationships. Using the ACS cancer screening recommendations, the charts were reviewed for appropriate cancer screening. Results: From manual chart review, 6,958 charts were reviewed and 201 (2

Full access

Grade 1 Chondrosarcoma of Bone: A Diagnostic and Treatment Dilemma

R. Lor Randall and William Gowski

: Churchill Livingstone ; 1983 . 2 Lee FY Mankin HJ Fondren G . Chondrosarcoma of bone: an assessment of outcome . J Bone Joint Surg Am 1999 ; 81 : 326 – 328 . 3 Springfield DS Gebhardt MC McGuire MH . Chondrosarcoma: a review

Full access

Four-Year Disease-Free Remission in a Patient With POLE Mutation–Associated Colorectal Cancer Treated Using Anti–PD-1 Therapy

Michael L. Durando, Sanjay V. Menghani, Jessica L. Baumann, Danny G. Robles, Tovah A. Day, Cyrus Vaziri, and Aaron J. Scott

remained disease-free 48 months after the first pembrolizumab infusion and was transitioned to annual surveillance follow-up in the clinic. Figure 4. CEA level over time, indicating important events (ie, treatment day, scan review) along the disease

Full access

NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018

Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Arnold J. Markowitz, Daniel C. Chung, Robert J. Mayer, Scott E. Regenbogen, Amie M. Blanco, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Michael J. Hall, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Xavier Llor, Patrick M. Lynch, June Mikkelson, Reid M. Ness, Thomas P. Slavin Jr, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer, and Ndiya Ogba

activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http

Full access

Malignant Biliary Tract Obstruction: Evaluation and Therapy

David Chu and Douglas G. Adler

participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscapecme.com/journal/jnccn ; (4) view